Multiple myeloma trials in United Kingdom

In United Kingdom 49 Also abroad 703

49 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Enrolling by invitation
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Where
Glasgow, London, Manchester, Newcastle upon Tyne
Age
1 year and over
People
500 worldwide
Run by
Autolus Limited
See details and how to joinNCT03628612
Phase 2Taking people
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Where
Bebington, Cardiff, Edinburgh, London, Oxford, Southampton, Sutton, Withington
Age
18 years and over
People
100 worldwide
Run by
CellCentric Ltd.
See details and how to joinNCT07096778
No phaseNot yet taking people in United Kingdom
REal World MAIA UK OutcomEs
Where
Wolverhampton
Age
18 years and over
People
300
Run by
The Royal Wolverhampton Hospitals NHS Trust
See details and how to joinNCT07532473
Phase 1/2Taking people
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Where
London, Manchester
Age
18 years and over
People
62 worldwide
Run by
Celgene
See details and how to joinNCT06988488 · EU 2025-522090-11-00
No phaseTaking people
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Where
Birmingham, London, Wolverhampton
Age
18 years and over
People
900 worldwide
Run by
Janssen-Cilag Ltd.
See details and how to joinNCT06285318
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Bournemouth, Bristol, Canterbury, Cardiff, Manchester, Oxford
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Bangor, Birmingham, Bodelwyddan, Bournemouth, Canterbury, Eastbourne, London, Maidstone, Milton Keynes, Oxford, Poole, Stoke-on-Trent, Wolverhampton, Worthing
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
Phase 1/2Taking people
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Where
Leicester, Oxford, Plymouth
Age
18 years and over
People
123 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00
Phase 1/2Taking people
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Where
London, Manchester
Age
18 years and over
People
220 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00
Phase 2/3Taking people
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Where
Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Leicester, Liverpool, London, Manchester, Metropolitan Borough of Wirral, Newcastle, Oxford, Sheffield, Southampton, Sutton
Age
1 year and over
People
30
Run by
Cancer Research UK
See details and how to joinNCT07440290
Phase 3Taking people
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Where
Edinburgh, London, Manchester
Age
18 years and over
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07764978
Phase 1/2Taking people
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Where
London, Manchester
Age
18 years and over
People
186 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06669247 · EU 2024-513126-39-00
Phase 3Not yet taking people in United Kingdom
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Where
Airdrie, Edinburgh, London, Nottingham, Plymouth, Portsmouth
Age
18 years and over
People
520 worldwide
Run by
AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00
Phase 3Taking people
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Where
Bristol, Eastbourne, Leeds, Liverpool, London
Age
18 years and over
People
1,226
Run by
University of Leeds
See details and how to joinNCT07649525
Phase 1/2Taking people
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Where
Bebington, Bristol, Cardiff, Derby, Edinburgh, Glasgow, Leicester, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford, Southampton, Stoke-on-Trent, Sutton
Age
18 years and over
People
250 worldwide
Run by
CellCentric Ltd.
See details and how to joinNCT04068597
Phase 2Taking people
Methods of T Cell Depletion Trial (MoTD)
Where
Birmingham, Bristol, Cambridge, Cardiff, Glasgow, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford, Plymouth, Sheffield, Sutton
Age
16 years to 70 years
People
400
Run by
University of Birmingham
See details and how to joinNCT04888741
Phase 3Taking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Leicester, Middlesbrough, Oxford, Plymouth, Wolverhampton
Age
18 years and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00
No phaseTaking people
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
Where
Wolverhampton
Age
18 years and over
People
70
Run by
The Royal Wolverhampton Hospitals NHS Trust
See details and how to joinNCT04234022
Phase 1/2Taking people
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Where
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
Age
12 years and over
People
606 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555
Phase 2/3Taking people
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Where
Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Leicester, London, Manchester, Metropolitan Borough of Wirral, Newcastle, Oxford, Sheffield, Southampton
Age
18 years and over
People
30
Run by
Cancer Research UK
See details and how to joinNCT05768178
Phase 1Taking people
A New Study Evaluating the Activity of Modular CAR T for mYeloma
Where
London
Age
18 years and over
People
27
Run by
University College, London
See details and how to joinNCT04795882
Phase 1/2Taking people
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Where
Leicester, Liverpool, London, Manchester, Oxford
Age
18 years and over
People
260 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT05372354 · EU 2023-509384-25-00
No phaseTaking people
Myeloma Novel Drug Discovery Ver 1.2
Where
Sutton
Age
18 years and over
People
250
Run by
Institute of Cancer Research, United Kingdom
See details and how to joinNCT05968417
Phase 3Taking people
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
Where
Aberdeen, Airdrie, Ayr, Barnsley, Basingstoke, Bath, Birmingham, Blackpool, Boston, Bournemouth, Bradford, Bristol, Burton-on-Trent, Cambridge, Carshalton, Cheltenham, Chester, Chesterfield, Chichester, Coventry, Derby, Dewsbury, Dudley, Dundee, East Kilbride, Edinburgh, Glasgow, Gloucester, Grantham, Grimsby, Halifax, Harrogate, Huddersfield, Hull, Inverness, Ipswich, Kidderminster, Kilmarnock, Leeds, Leicester, Lincoln, Liverpool, London, Maidstone, Manchester, Melrose, Middlesbrough, Milton Keynes, Newcastle, North Shields, Norwich, Nottingham, Oldham, Oxford, Paisley, Plymouth, Pontefract, Prescot, Reading, Redditch, Royal Tunbridge Wells, Salford, Salisbury, Scunthorpe, Sheffield, Southampton, Stafford, St Helens, Stockport, Stoke-on-Trent, Sunderland, Sutton in Ashfield, Swansea, Taunton, Tooting, Wakefield, Winchester, Wishaw, Wolverhampton, Worcester, Worthing
Age
18 years and over
People
406
Run by
University of Leeds
See details and how to joinNCT03562169